Biognosys’ Post

We are pleased to be an Expertise Partner for the 6th Annual Neuroimmunology Drug Development Summit. Alamar's own Christopher Bunker, Ph.D., M.B.A. will be highlighting our #NULISA Platform and how the ultrasensitive and multiplex NULISAseq CNS Disease Panel 120 is revolutionizing neurodegenerative research. Meet with Dr. Bunker and Brad Nawa to discover the only immunoassay technology with the sensitivity to see #pTau217 as well as ~120 other CNS disease-related proteins from a single 10uL blood sample. Join us to explore the future of neuroimmunology! Learn more: https://ow.ly/sHrB50R0fCm #proteomics #immunoassay

🔬Citation Break!📖 This citation seeks to characterize antibodies found in intravenous immunoglobulin (IVIG) products against the Tau-441 protein to further therapeutic research in Alzheimer's Disease. Our Tau-441 (T-1001) was used to test against the antibodies in assays such as ELISA. rPeptide Tau products are suitable as standards, for aggregation studies, or other experimentation. Paper: https://t.ly/fCFJ4 Tau-441: https://t.ly/aZ8pW #Research #Development #rPeptide #Tau441

Gain practical advice on how to utilize advanced molecular testing strategies to not miss rare actionable biomarkers, and how to use new targeted treatment options to optimize care of NSCLC patients with specific molecular alterations. https://lnkd.in/esgyAa7w

How do you target T-cell malignancies without impacting healthy T cells? Michael Girardi et al., from Yale School of Medicine developed a CAR-T therapeutic that targets  a specific T cell receptor (TCR) clone, known as TRBV20-1 that is expressed by malignant T cells. Their approach involved engineering and optimizing a commercially available murine Vβ2 antibody, leveraging its amino acid sequence obtained through REmAb de novo antibody sequencing. The resulting CAR-Vβ2 T cells demonstrated specific elimination of Vβ2+ malignant T cells both in vivo and in vitro. This innovative strategy holds great promise for advancing targeted therapies against T-cell malignancies, potentially offering a more precise and effective treatment option for patients. Check out the case study: https://lnkd.in/gNNTMZZj #ScienceInAction #CGT #CellTherapy #DeNovoSequencing

At MitogenDx, we leverage cutting-edge technologies to advance diagnostic capabilities across diverse medical disciplines. Our offerings include: Simoa™ Based Assays: Achieve unparalleled sensitivity with femtogram-level biomarker detection across multiple sample types. Perfect for autoimmunity, inflammation, and oncology. Line Immunoassays (LIA): Differentiate antibody reactivity to multiple antigens on a single test strip, providing comprehensive antibody profiling with high specificity. Cell Based Assays: Utilize transfected cells to detect antibodies against specific antigens, enabling multiplexing and precise antibody identification. Luminex Assays: Employ microsphere-based technology for high-throughput, multiplex detection of analytes, ensuring rapid and accurate bioanalysis. Explore how these technologies are transforming diagnostics at MitogenDx. Learn more on this page: https://lnkd.in/dZREFm4T #MitogenDx #DiagnosticInnovation #HealthcareTechnology #PrecisionMedicine #Bioanalysis #ClinicalDiagnostics #MedicalResearch #Diagnostics

Proud to be an Expertise Partner for the 12th Annual #Alzheimer's and #Parkinson's Drug Development Summit in Boston, MA, April 23-25. Alamar's Christopher Bunker, Ph.D., M.B.A. will be providing an exclusive look at #NULISA and its applications in CNS disease research. He'll also dive into the new #NULISAseq CNS Disease Panel 120 for ultra-sensitive and multiplex protein biomarker detection that includes #pTau217 and ~120 other important neurogenerative targets. https://ow.ly/Vqqm50Rlui4 #proteomics

Meet us today at hubXchange's Immuno-Oncology Xchange Boston 2024! Be sure to attend the roundtable discussion, "Multiomic immune biomarker selection for novel IO response and toxicity assessment: tissue, blood, plasma, or all of the above?" led by Michael Goldberg, PhD, VP, Research & Development at BostonGene. This session will explore using immune biomarkers to enhance drug development and patient outcomes. The focus will be on current applications, technological advancements, novel approaches and necessary validation and regulatory processes, highlighting how these strategies can improve therapeutic results and personalize treatments. https://lnkd.in/ej7CAYTT

New drug binding sites on the angiotensin II type 1 (AT1) receptor, which plays a major role in cardiovascular regulation, have been uncovered by scientists at City of Hope, a cancer research organisation in the USA. The discovery of these sites significantly expands the scope for scientists working towards designing targeted therapies for cardiovascular disease. Researcher Nagarajan Vaidehi said: “We identified previously unknown domains and mechanisms within the AT1 receptor that enable it to bind with molecules and transmit specific signals. Our work strongly suggests these regions offer promising targets for new treatments for cardiovascular diseases.” He added that multiple drug binding sites exist, paving the way for the development of a new class of heart disease medicines with fewer side effects. Read the full paper in Science Signaling here: https://bit.ly/3P1g5UK For more scientific news like this, follow FIP's Board of Pharmaceutical Sciences on Twitter [https://lnkd.in/d7gCCct] & LinkedIn: [https://lnkd.in/ettEXW5v] #angiotensin #CardiovascularDisease #DrugTreatment

Could a patient’s gut microbiome influence how they will respond to immunotherapy? Join Rachel Newsome, PhD for a webinar on Feb. 21st featuring the findings from a study of Bacteroides-enhanced gut microbiomes associated with an enhanced response to anti-PD-1 therapy in NSCLC patients. Characterization of live Bacteroides isolates led to the discovery of a novel influential metabolite that stimulates IFNγ in CD8+ T cells, and in combination with anti-PD-1 therapy, significantly reduces tumor growth in an NSCLC mouse model. Save your seat for this informative discussion and learn about the high-throughput isolation and cultivation methods that, not only enabled this discovery but can empower any microbiome-based product or drug development program. Register here: https://hubs.li/Q02jnVps0 #MicrobialIsolation #Immunotherapy #Microbiome #Webinar #DrugDiscovery #HighThroughputCultivation #Culturomics #Prospector

🧠🔬 Interesting research news in cluster headache! A recent study explored the role of calcitonin gene-related peptide (CGRP) in cluster headaches to understand why only episodic cluster headache responds to CGRP monoclonal antibodies. 💡 Key findings include: 📉 CGRP levels are generally lower in individuals with cluster headache compared to controls. 📈 In episodic cluster headache, CGRP is higher during bouts than in remission. 📊 CGRP levels in a bout were not different from chronic cluster headache. The study suggests that plasma CGRP is not a reliable diagnostic biomarker for cluster headaches. Since the role of CGRP in cluster headaches is complex, further research is needed. Full Study: https://lnkd.in/em_x9HVs #Research #ClusterHeadache